(EVK) Evonik Industries - Ratings and Ratios
Exchange: XETRA •
Country: Germany •
Currency: EUR •
Type: Common Stock •
ISIN: DE000EVNK013
Specialty Additives, Nutrition Care, Smart Materials, Technology Infrastructure
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 8.63% |
| Yield on Cost 5y | 5.69% |
| Yield CAGR 5y | 0.43% |
| Payout Consistency | 96.5% |
| Payout Ratio | 86.0% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 19.5% |
| Value at Risk 5%th | 31.0% |
| Relative Tail Risk | -3.31% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.56 |
| Alpha | -21.12 |
| CAGR/Max DD | -0.18 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.489 |
| Beta | 0.227 |
| Beta Downside | 0.446 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.00% |
| Mean DD | 12.72% |
| Median DD | 11.66% |
Description: EVK Evonik Industries January 07, 2026
Evonik Industries AG (XETRA:EVK) is a global specialty chemicals producer headquartered in Essen, Germany, operating across four business segments: Specialty Additives, Nutrition & Care, Smart Materials, and Technology & Infrastructure. The company supplies a wide range of high-performance chemicals-from polyurethane foam additives and curing agents for coatings to amino acids for animal nutrition and biocompatible materials for medical devices-serving markets in Asia-Pacific, Europe, the Middle East, Africa, the Americas, and beyond.
Key recent metrics: FY 2023 revenue reached €15.2 billion, with an adjusted EBITDA margin of roughly 14%, reflecting strong pricing power in the Specialty Additives and Smart Materials divisions. Growth is being driven by secular trends such as the automotive sector’s shift toward lightweight, fuel-efficient vehicles (boosting demand for polyamide 12 and specialty polymers) and the broader industrial push for decarbonisation, which fuels sales of high-efficiency additives and digital process-optimization services. The Nutrition & Care segment benefits from rising global protein demand, supporting higher volumes of methionine and lysine for animal feed.
For a deeper quantitative assessment, consider reviewing ValueRay’s detailed EVK valuation model.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (95.0m TTM) > 0 and > 6% of Revenue (6% = 856.0m TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA -3.69pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 13.02% (prev 10.46%; Δ 2.56pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 1.22b > Net Income 95.0m (YES >=105%, WARN >=100%) |
| Net Debt (4.04b) to EBITDA (1.78b) ratio: 2.27 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.54 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (466.0m) change vs 12m ago 0.30% (target <= -2.0% for YES) |
| Gross Margin 22.56% (prev 25.25%; Δ -2.68pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 74.87% (prev 77.51%; Δ -2.64pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.21 (EBITDA TTM 1.78b / Interest Expense TTM 217.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.87
| (A) 0.10 = (Total Current Assets 5.30b - Total Current Liabilities 3.45b) / Total Assets 18.55b |
| (B) 0.40 = Retained Earnings (Balance) 7.41b / Total Assets 18.55b |
| (C) 0.03 = EBIT TTM 480.0m / Avg Total Assets 19.05b |
| (D) 0.71 = Book Value of Equity 7.18b / Total Liabilities 10.13b |
| Total Rating: 2.87 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 46.71
| 1. Piotroski 3.0pt |
| 2. FCF Yield 4.00% |
| 3. FCF Margin 2.87% |
| 4. Debt/Equity 0.54 |
| 5. Debt/Ebitda 2.27 |
| 6. ROIC - WACC (= 1.79)% |
| 7. RoE 1.08% |
| 8. Rev. Trend -82.32% |
| 9. EPS Trend -39.59% |
What is the price of EVK shares?
As of January 07, 2026, the stock is trading at EUR 13.56 with a total of 624,428 shares traded.
Over the past week, the price has changed by +1.50%, over one month by +5.20%, over three months by -7.69% and over the past year by -14.12%.
Over the past week, the price has changed by +1.50%, over one month by +5.20%, over three months by -7.69% and over the past year by -14.12%.
Is EVK a buy, sell or hold?
Evonik Industries has no consensus analysts rating.
What are the forecasts/targets for the EVK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 15.5 | 14.5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 14.1 | 3.6% |
EVK Fundamental Data Overview January 06, 2026
Market Cap USD = 7.25b (6.20b EUR * 1.1705 EUR.USD)
Market Cap EUR = 6.20b (6.20b EUR * 1.0 EUR.EUR)
P/E Trailing = 63.3333
P/E Forward = 19.9203
P/S = 0.4345
P/B = 0.7429
P/EG = 5.0637
Beta = 0.735
Revenue TTM = 14.27b EUR
EBIT TTM = 480.0m EUR
EBITDA TTM = 1.78b EUR
Long Term Debt = 3.66b EUR (from longTermDebt, last quarter)
Short Term Debt = 830.0m EUR (from shortTermDebt, last quarter)
Debt = 4.49b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.04b EUR (from netDebt column, last quarter)
Enterprise Value = 10.24b EUR (6.20b + Debt 4.49b - CCE 454.0m)
Interest Coverage Ratio = 2.21 (Ebit TTM 480.0m / Interest Expense TTM 217.0m)
FCF Yield = 4.00% (FCF TTM 409.0m / Enterprise Value 10.24b)
FCF Margin = 2.87% (FCF TTM 409.0m / Revenue TTM 14.27b)
Net Margin = 0.67% (Net Income TTM 95.0m / Revenue TTM 14.27b)
Gross Margin = 22.56% ((Revenue TTM 14.27b - Cost of Revenue TTM 11.05b) / Revenue TTM)
Gross Margin QoQ = 18.17% (prev 26.61%)
Tobins Q-Ratio = 0.55 (Enterprise Value 10.24b / Total Assets 18.55b)
Interest Expense / Debt = 1.25% (Interest Expense 56.0m / Debt 4.49b)
Taxrate = -32.47% (negative due to tax credits) (25.0m / -77.0m)
NOPAT = 635.8m (EBIT 480.0m * (1 - -32.47%)) [negative tax rate / tax credits]
Current Ratio = 1.54 (Total Current Assets 5.30b / Total Current Liabilities 3.45b)
Debt / Equity = 0.54 (Debt 4.49b / totalStockholderEquity, last quarter 8.35b)
Debt / EBITDA = 2.27 (Net Debt 4.04b / EBITDA 1.78b)
Debt / FCF = 9.88 (Net Debt 4.04b / FCF TTM 409.0m)
Total Stockholder Equity = 8.76b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.51% (Net Income 95.0m / Total Assets 18.55b)
RoE = 1.08% (Net Income TTM 95.0m / Total Stockholder Equity 8.76b)
RoCE = 3.86% (EBIT 480.0m / Capital Employed (Equity 8.76b + L.T.Debt 3.66b))
RoIC = 6.45% (NOPAT 635.8m / Invested Capital 9.85b)
WACC = 4.67% (E(6.20b)/V(10.69b) * Re(6.85%) + D(4.49b)/V(10.69b) * Rd(1.25%) * (1-Tc(-0.32)))
Discount Rate = 6.85% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 78.62% ; FCFE base≈706.6m ; Y1≈723.2m ; Y5≈803.6m
Fair Price DCF = 30.37 (DCF Value 14.15b / Shares Outstanding 466.0m; 5y FCF grow 2.21% → 3.0% )
EPS Correlation: -39.59 | EPS CAGR: -36.64% | SUE: -1.08 | # QB: 0
Revenue Correlation: -82.32 | Revenue CAGR: -4.88% | SUE: -0.53 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.33 | Chg30d=+0.000 | Revisions Net=-2 | Analysts=2
EPS next Year (2026-12-31): EPS=1.23 | Chg30d=-0.036 | Revisions Net=-3 | Growth EPS=-1.9% | Growth Revenue=+0.1%
Market Cap EUR = 6.20b (6.20b EUR * 1.0 EUR.EUR)
P/E Trailing = 63.3333
P/E Forward = 19.9203
P/S = 0.4345
P/B = 0.7429
P/EG = 5.0637
Beta = 0.735
Revenue TTM = 14.27b EUR
EBIT TTM = 480.0m EUR
EBITDA TTM = 1.78b EUR
Long Term Debt = 3.66b EUR (from longTermDebt, last quarter)
Short Term Debt = 830.0m EUR (from shortTermDebt, last quarter)
Debt = 4.49b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.04b EUR (from netDebt column, last quarter)
Enterprise Value = 10.24b EUR (6.20b + Debt 4.49b - CCE 454.0m)
Interest Coverage Ratio = 2.21 (Ebit TTM 480.0m / Interest Expense TTM 217.0m)
FCF Yield = 4.00% (FCF TTM 409.0m / Enterprise Value 10.24b)
FCF Margin = 2.87% (FCF TTM 409.0m / Revenue TTM 14.27b)
Net Margin = 0.67% (Net Income TTM 95.0m / Revenue TTM 14.27b)
Gross Margin = 22.56% ((Revenue TTM 14.27b - Cost of Revenue TTM 11.05b) / Revenue TTM)
Gross Margin QoQ = 18.17% (prev 26.61%)
Tobins Q-Ratio = 0.55 (Enterprise Value 10.24b / Total Assets 18.55b)
Interest Expense / Debt = 1.25% (Interest Expense 56.0m / Debt 4.49b)
Taxrate = -32.47% (negative due to tax credits) (25.0m / -77.0m)
NOPAT = 635.8m (EBIT 480.0m * (1 - -32.47%)) [negative tax rate / tax credits]
Current Ratio = 1.54 (Total Current Assets 5.30b / Total Current Liabilities 3.45b)
Debt / Equity = 0.54 (Debt 4.49b / totalStockholderEquity, last quarter 8.35b)
Debt / EBITDA = 2.27 (Net Debt 4.04b / EBITDA 1.78b)
Debt / FCF = 9.88 (Net Debt 4.04b / FCF TTM 409.0m)
Total Stockholder Equity = 8.76b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.51% (Net Income 95.0m / Total Assets 18.55b)
RoE = 1.08% (Net Income TTM 95.0m / Total Stockholder Equity 8.76b)
RoCE = 3.86% (EBIT 480.0m / Capital Employed (Equity 8.76b + L.T.Debt 3.66b))
RoIC = 6.45% (NOPAT 635.8m / Invested Capital 9.85b)
WACC = 4.67% (E(6.20b)/V(10.69b) * Re(6.85%) + D(4.49b)/V(10.69b) * Rd(1.25%) * (1-Tc(-0.32)))
Discount Rate = 6.85% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 78.62% ; FCFE base≈706.6m ; Y1≈723.2m ; Y5≈803.6m
Fair Price DCF = 30.37 (DCF Value 14.15b / Shares Outstanding 466.0m; 5y FCF grow 2.21% → 3.0% )
EPS Correlation: -39.59 | EPS CAGR: -36.64% | SUE: -1.08 | # QB: 0
Revenue Correlation: -82.32 | Revenue CAGR: -4.88% | SUE: -0.53 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.33 | Chg30d=+0.000 | Revisions Net=-2 | Analysts=2
EPS next Year (2026-12-31): EPS=1.23 | Chg30d=-0.036 | Revisions Net=-3 | Growth EPS=-1.9% | Growth Revenue=+0.1%